Ponad 7000 publikacji medycznych!
Statystyki za 2021 rok:
odsłony: 8 805 378
Artykuły w Czytelni Medycznej o SARS-CoV-2/Covid-19

Poniżej zamieściliśmy fragment artykułu. Informacja nt. dostępu do pełnej treści artykułu tutaj
© Borgis - New Medicine 4/2003, s. 121-124
Tomasz Kornatowski1, Kornelia Kedziora-Kornatowska2, Hanna Pawluk3, Jozef Kedziora3, Leszek Szadujkis-Szadurski1, Robert Pawluk3, Jolanta Czuczejko3, Jadwiga Motyl2
The influence of perindopril on lipid peroxidation and the oxidase activity of ceruloplasmin in the blood of old age patients with primary hypertension
1 Department of Pharmacology and Therapy, L. Rydygier Medical Academy of Bydgoszcz, Poland
Head: prof. Leszek Szadujkis-Szadurski, MD, PhD
2 Department and Clinic of Geriatrics, L. Rydygier Medical Academy of Bydgoszcz, Poland
Head: dr Kornelia Kedziora-Kornatowska, MD, PhD
3 Department of Biochemistry, L. Rydygier Medical Academy of Bydgoszcz, Poland
Head: prof. Jozef Kedziora, MD, PhD
Background: The purpose of this work was to estimate oxidase activity of ceruloplasmin and lipid peroxidation processes in the blood of elderly patients with primary hypertension. Furthermore, the influence of treatment with ACEi, perindopril, on the examined parameters was determined.
Material and methods: The research was carried out on 28 patients (65-91 yrs) with primary hypertension, treated with perindopril for 6 weeks, and normotensive persons who constituted the control groups: 25 (65-96 yrs – K1) and 23 (22-41 yrs – K2). The oxidase activity of ceruloplasmin was measured in serum by Ravin´s method, and the concentration of malondialdehyde (MDA) in erythrocytes according to Placer et al. Patients with hypertension underwent an examination after 7 days and 6 weeks from the beginning of therapy.
Results: It was found that in the group of patients with hypertension, the activity of ceruloplasmin was significantly higher in comparison to the activity in the control groups (K1 and K2). The concentration of MDA in erythrocytes of patients with hypertension was significantly higher than in the control groups (K1 and K2). In patients with hypertension, after 7 days of therapy a substantial decrease in the oxidative activity of ceruloplasmin was found, but the lowest value was observed after 6 weeks of therapy. These values were significantly lower than those from the control groups.
Conclusions: The results confirm the intensification of oxidative stress in elderly patients with primary hypertension and point to the beneficial antioxidant effect of perindopril.
Ageing and hypertension are essential factors in the risk of cardiovascular complications (1, 2). Such changes are significantly more intense in elderly patients with primary hypertension in comparison to persons of the same age but without hypertension (3, 4). In fact, an intensification of oxidative stress, which is the imbalance of pro-and antioxidative processes towards oxidation, is observed in the etiopathogenesis of both processes (5, 6). It has also been shown that reactive oxygen species play a significant role in the damage and dysfunction of vessel endothelium, and in hypertrophy and hyperplasia of cells of the vascular wall of smooth muscles (7, 8). Furthermore, it has been shown that one of the significant factors intensifying oxidative stress and also causing hypertrophy of the vascular wall and vascular contractility is angiotensin II. Angiotensin II released locally in the vascular wall plays a crucial role in the pathophysiology of hypertension (9). One of the possible action mechanisms of angiotensin converting enzyme inhibitors, apart from decreasing the level of angiotensin II and increasing the level of bradykinin, is an influence on oxidative stress in vessels. Research carried out by many authors has evaluated the antioxidative characteristics of various angiotensin convertase inhibitors by way of the influence on the activity of key cell antioxidative enzymes (superoxide dismutase, catalase, glutathione peroxidase), or the level of other antioxidants and lipid peroxidation products. However, such an influence on the activity of ceruloplasmin has not been evaluated (10, 11, 12).
The aim of this work was to evaluate the oxidase activity of ceruloplasmin and the process of lipid peroxidation in the blood of elderly patients with primary hypertension. In addition, the influence of treatment with angiotensin convertase inhibitor, perindopril, on the examined parameters was determined.
The research was carried out on 25 healthy subjects (K1) between 65-96 years of age (average 74.3 ± 4.8 years) and on 23 healthy subjects (K2) between 22-41 years of age (average 37.4 ± 8.2 years), and on 28 persons between 65-91 years of age (average 74.7 ± 8.1 years) with 1st or 2nd level primary hypertension (according to the JNC-VI criteria and WHO/ISH recommendations) (13, 14).
The clinical characteristics of the examined persons are shown in table 1.
Table 1. The clinical characteristics of the examined persons.
ParameterNormotensive SubjectsEssential Hypertensive Patients (EAH)
Before treatment (EAH)After treatment (EAH+P)
Number of subject25232828
Age (y)74.3 ? 4.8 37.4 ? 8.2a74.7 ? 8.1 74.7 ? 8.1
Sex: M/F11/149/1412/1612/16
Smoking (yes/no)NoNoNoNo
Body mass index (kg/m2)24.1? 2.122.6 ? 3.425,3 ? 2.824.9 ? 3.6
Systolic blood pressure (mmHg)130.4 ? 6.7118.7 ? 4.6168.6 ? 10.4b132.3 ? 6.4
Diastolic blood pressure (mmHg)81.7 ? 8.474.6 ? 4.6103.2 ? 10.4b84.1 ? 8.5
Plasma glucose (mg/dl)82.7 ? 4.979.1 ? 3.785.6 ? 5.588. 4 ? 6.8
Plasma total cholesterol (mg/dl)190.6 ? 12.3181.3 ? 9.6196.7 ? 8.6191.3 ? 10.6
Plasma HDL cholesterol (mg/dl)43.4 ? 5.141.7 ? 7.342.6 ? 6.941.0 ? 5.6
Plasma LDL cholesterol (mg/dl)109.3 ? 8.4105.3 ? 7.2110.3 ? 8.1110.8 ? 9.6
a p <0,05 (K2 vs K1, EAH, EAH+P)
b p <0,05 (EAH vs K1, K2, EAH+P)
A permit for carrying out this research was obtained from the local Bioethics Committee in the Medical University of Bydgoszcz (KB/53/2002/), as well as written agreements from the subjects.

Powyżej zamieściliśmy fragment artykułu, do którego możesz uzyskać pełny dostęp.
Mam kod dostępu
  • Aby uzyskać płatny dostęp do pełnej treści powyższego artykułu albo wszystkich artykułów (w zależności od wybranej opcji), należy wprowadzić kod.
  • Wprowadzając kod, akceptują Państwo treść Regulaminu oraz potwierdzają zapoznanie się z nim.
  • Aby kupić kod proszę skorzystać z jednej z poniższych opcji.

Opcja #1


  • dostęp do tego artykułu
  • dostęp na 7 dni

uzyskany kod musi być wprowadzony na stronie artykułu, do którego został wykupiony

Opcja #2


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 30 dni
  • najpopularniejsza opcja

Opcja #3


  • dostęp do tego i pozostałych ponad 7000 artykułów
  • dostęp na 90 dni
  • oszczędzasz 28 zł
1. Kannel W. et al.: Systolic versus diastolic blood pressure and risk of coronary artery disease: the Framingham Study. Am. J. Cardiol. 1971; 27:335-46. 2. Forette B.: Hypertension in very old subjects. Clin. Exp. Hypertens. 1999; 21:917-25. 3. Soltis E.F.: Effect of age on blood pressure and membrane dependent vascular responses in the rat. Circ. Res. 1987; 61:889-97. 4. Taddei S. et al.: Aging and endothelial function in normotensive subjects and essential hypertensive patients. Circulation 1995; 91:1981-7. 5. Harman D.: Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956; 11:298-300. 6. Cai H., Harrison D.G.: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 2000; 87:840-4. 7. Zalba G. et al.: Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction? Nephrol. Dial. Transplant. 2001; 16 (suppl. 1):2-5. 8. Li P.F. et al.: Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 1997; 96:3602-9. 9. Romero J.C., Reckelhoff J.F.: Role of angiotensin and oxidative stress in essential hypertension. Hypertension 1999; 34(part 2):943-9. 10. Liao D.F., Chen X.: Prostacyclin-mediated protection by angiotensin-converting enzyme inhibitors against injury of aortic endothelium by free-radicals. Cardioscience 1992; 3:79-84. 11. Bartosz M. et al.: Antioxidant and prooxidant properties of captopril and enalapril. Free Radic. Bio. Med. 1997; 23:729-35. 12. Floris G. et al.: The physiopathological significance of ceruloplasmin. A possible therapeutic approach. Biochem. Pharmacol. 2000; 60:1736-41. 13. JNC. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 1997; 157:2413-46. 14. The Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Managment of Hypertension. J. Hypertens. 1999: 17:151-83. 15. Ravin H.: An improved colorimetric enzymatic assay of ceruloplasmin. J. Lab. Clin. Med. 1961; 58/1:161-8. 16. Placer Z. et al.: Estimation of products of lipid peroxidation, malondialdehyde, in biochemical systems. Anal. Biochem. 1966; 16:359-64. 17. Kocemba J. et al.: Distribution of blood pressure and prevalence of arterial hypertension in the old population of Cracow. Mat. Med. Pol. 1991; 1:33-5. 18. Schöneich C.: Reactive oxygen species and biological aging: a mechanistic approach. Exp. Gerontol. 1999; 34:19-34. 19. Cutler R.G.: Antioxidants and aging. A. J. Clin. Nutr. 1991; 53:373 S-9S. 20. Ruiz-Ortega M. et al.: Role of the renin-angiotensin system in vascular diseases. Expanding the field. Hypertension 2001; 38:1382-7. 21. Messerli F.H. et al.: Essential hypertension in the elderly: Haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 29:983-5. 22. Anderson S.: Ageing and the renin-angiotensin system. Nephrol. Dial. Transplant. 1997;12:1093-4. 23. Kędziora-Kornatowska K., Luciak M.: Effect of angiotensin convertase inhibitors on lipid peroxidation and peroxyl radical-trapping capacity in rats with experimental diabetes. Biochem. Mol. Biol. Int. 1998; 42:246-9. 24. De Cavanagh E.M.V. et al.: Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Letters 1995; 361:22-4. 25. Dijordjevic V.B. et al.: Changes of lipid peroxidation and antioxidative factors level in blood of patients treated with ACE inhibitors. Clin. Nephrol. 1997; 47:243-7. 26. Hayek T. et al.: The angiotensin-converting enzyme inhibitor, fosinopril and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoproteine E deficient mice. Cardiovasc. Res. 1999; 44:579-87.
Adres do korespondencji:

New Medicine 4/2003
Strona internetowa czasopisma New Medicine